- Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
- Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Arvinas Announces Chief Financial Officer Transition
More ▼
Key statistics
On Friday, Arvinas Inc (ARVN:NSQ) closed at 32.68, 140.83% above the 52 week low of 13.57 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.97 |
---|---|
High | 33.08 |
Low | 31.40 |
Bid | 31.00 |
Offer | 33.25 |
Previous close | 32.11 |
Average volume | 642.67k |
---|---|
Shares outstanding | 68.43m |
Free float | 62.39m |
P/E (TTM) | -- |
Market cap | 2.24bn USD |
EPS (TTM) | -6.05 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼